SCHEMBL30216089

SCHEMBL30216089

CC(=O)N[C@H]1[C@@H](O[C@H]2C(O)O[C@H](CO)[C@H](O)[C@@H]2O)O[C@H](CO)[C@H](O)[C@@H]1O

nearest known ligand 0.63

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ CD69 Q07108 1/20 0.63
▸ ALDH1A1 P00352 2/20 0.60
▸ THRB P10828 1/20 0.60
▸ MAPK1 P28482 2/20 0.57
▸ LGALS3 P17931 2/20 0.54
▸ LGALS8 O00214 1/20 0.54
▸ LGALS4 P56470 1/20 0.54
▸ CHIA Q9BZP6 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29407989 1.00 CD69 (0.63) CD69ALDH1A1THRBMAPK1LGALS3
SCHEMBL29966546 1.00 CD69 (0.63) CD69ALDH1A1THRBMAPK1LGALS3
SCHEMBL8516937 0.93 CD69 (0.61) CD69ALDH1A1THRBMAPK1LGALS3
SCHEMBL4809869 0.93 CD69 (0.61) CD69ALDH1A1THRBMAPK1LGALS3
SCHEMBL9566045 0.93 CD69 (0.61) CD69ALDH1A1THRBMAPK1LGALS3
SCHEMBL4809860 0.93 CD69 (0.61) CD69ALDH1A1THRBMAPK1LGALS3
SCHEMBL16298755 0.93 CD69 (0.61) CD69ALDH1A1THRBMAPK1LGALS3
SCHEMBL9566182 0.93 CD69 (0.61) CD69ALDH1A1THRBMAPK1LGALS3
SCHEMBL9566048 0.93 CD69 (0.61) CD69ALDH1A1THRBMAPK1LGALS3
SCHEMBL30703113 0.93 CD69 (0.61) CD69ALDH1A1THRBMAPK1LGALS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4508429-A1 MEANS AND METHODS FOR HIGH-THROUGHPUT GLYCOPROFILING OF PROTEINS Glycanostics s.r.o. (SK) 2025-02-19 — — EP claimed
EP-4396583-A1 USE OF LECTINS TO DETERMINE MAMMAGLOBIN-A GLYCOFORMS IN BREAST CANCER Glycanostics s.r.o. (SK) 2024-07-10 — — EP claimed
EP-4392780-A1 GLYCOPROTEIN BIOMARKERS FOR DIAGNOSING CANCER Glycanostics s.r.o. (SK) 2024-07-03 — — EP claimed
EP-4381291-A1 STANDARD FOR GLYCOPROFILING OF PROTEINS Glycanostics s.r.o. (SK) 2024-06-12 — — EP claimed
WO-2023198337-A1 MEANS AND METHODS FOR HIGH-THROUGHPUT GLYCOPROFILING OF PROTEINS GLYCANOSTICS S.R.O. (SK) 2023-10-19 — — WO claimed
WO-2023041565-A1 USE OF LECTINS TO DETERMINE MAMMAGLOBIN-A GLYCOFORMS IN BREAST CANCER GLYCANOSTICS S.R.O (SK) 2023-03-23 — — WO claimed
WO-2023025927-A1 GLYCOPROTEIN BIOMARKERS FOR DIAGNOSING CANCER GLYCANOSTICS S.R.O (SK) 2023-03-02 — — WO claimed
WO-2023012352-A1 STANDARD FOR GLYCOPROFILING OF PROTEINS GLYCANOSTICS S.R.O. (SK) 2023-02-09 — — WO claimed
EP-4508429-A1 MEANS AND METHODS FOR HIGH-THROUGHPUT GLYCOPROFILING OF PROTEINS Glycanostics s.r.o. (SK) 2025-02-19 — — EP disclosed
EP-4396583-A1 USE OF LECTINS TO DETERMINE MAMMAGLOBIN-A GLYCOFORMS IN BREAST CANCER Glycanostics s.r.o. (SK) 2024-07-10 — — EP disclosed
EP-4392780-A1 GLYCOPROTEIN BIOMARKERS FOR DIAGNOSING CANCER Glycanostics s.r.o. (SK) 2024-07-03 — — EP disclosed
EP-4381291-A1 STANDARD FOR GLYCOPROFILING OF PROTEINS Glycanostics s.r.o. (SK) 2024-06-12 — — EP disclosed
WO-2023198337-A1 MEANS AND METHODS FOR HIGH-THROUGHPUT GLYCOPROFILING OF PROTEINS GLYCANOSTICS S.R.O. (SK) 2023-10-19 — — WO disclosed
WO-2023041565-A1 USE OF LECTINS TO DETERMINE MAMMAGLOBIN-A GLYCOFORMS IN BREAST CANCER GLYCANOSTICS S.R.O (SK) 2023-03-23 — — WO disclosed
WO-2023025927-A1 GLYCOPROTEIN BIOMARKERS FOR DIAGNOSING CANCER GLYCANOSTICS S.R.O (SK) 2023-03-02 — — WO disclosed
WO-2023012352-A1 STANDARD FOR GLYCOPROFILING OF PROTEINS GLYCANOSTICS S.R.O. (SK) 2023-02-09 — — WO disclosed
Send feedback